Provided herein are ATXN2 RNAi agents and compositions comprising an ATXN2 RNAi agent. Also provided herein are methods of using the ATXN2 RNAi agents or compositions comprising an ATXN2 RNAi agent in reducing ATXN2 expression and/or treating ATXN2-associated neurological disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Provided herein are PLIN1 RNAi agents and compositions comprising a PLIN1 RNAi agent. Also provided herein are methods of using the PLIN1 RNAi agents or compositions comprising a PLIN1 RNAi agent for reducing PLIN1 expression, and/or treating PLIN1 associated metabolic disorder in a subject.
Plunger drive systems used with injectors to expel a fluid drug for injection into a patient include a housing and a plunger rod that extends from the housing. The plunger rod includes a first leg and a second leg individually coupled with separate rollers over one portion of the first leg and second leg and engaged together over another portion of the first leg and second leg to form a column. The legs may include a reinforcement member. The first leg and second leg meet at a location between the rollers and are engaged with one another through complementary registration surfaces. When the rollers are rotated, typically through action of an electric motor, the rollers rotate in opposite directions to increase a length of the column. The column may be operatively coupled to a plunger of a syringe to dispense a fluid drug as the column increases in length.
Disclosed are compounds or pharmaceutically acceptable salts thereof according to formulae IA, IB, or IC as well as pharmaceutical compositions, and methods of use thereof: Formula (IA), (IB), (IC), wherein moieties A and B are further described herein. In certain embodiments, a compound disclosed herein is a 5'-AMP-activated protein kinase ('AMPK') agonist.
C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
Provided are TrkA RNAi agents for reducing expression of TrkA, which comprise a sense strand and an antisense strand forming a double stranded RNA (dsRNA), compositions comprising these RNAi agents and methods of their use.
Disclosed herein are compounds of formula (I): (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein is a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive. Further disclosed herein is a method for preventing or treating a disease or condition through the modulation of the glucagon receptor using a compound of formula (I), or a pharmaceutically acceptable salt thereof.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
Provided herein are ALK7 RNAi agents, conjugates thereof, and compositions comprising an ALK7 RNAi agent. Also provided herein are methods of using the ALK7 RNAi agents or compositions comprising an ALK7 RNAi agent for reducing ACVR1C expression, and/or treating ALK7 associated metabolic disorder in a subject.
An apparatus is described for concentrating biomolecules in solution, such as oligonucleotide-containing solutions, via tangential flow filtration (TFF), where the apparatus can concentrate the oligonucleotides to a concentration>100 mg/mL. Also described are methods of concentrating a biomolecule-containing solution, such as oligonucleotide-containing solutions, via TFF for high dose/low volume applications.
The techniques described herein relate to computerized methods and apparatus for determining a dose injected into a user by one or more medication delivery devices. Data is accessed that is indicative of an injection event group that includes one or more injection events associated with one or more medication delivery devices. The injection event group is processed to determine the dose injected into the user based on one or more of whether the injection event is associated with a medication delivery device change, a dose size of one or more of the injection events, a position of one or more of the injection events in the injection event group, and/or a time period between one or more injection events to a next injection event in the injection event group.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
Medication delivery devices are provided having a housing comprising a reservoir sized sufficiently to hold medication, a dose button being rotatable relative to the housing to select a dose size of the medication for an injection, a printed circuit board, a switch mounted to the printed circuit board, and a controller in communication with the switch. The controller is configured to generate a first count of a set of signals using a first counting technique, generate a second count of the set of signals using a second counting technique, and determine, based on the first and second count, reliability data of the first and/or second count. The controller can connect, using a wireless communication module, to a remote computing device to wirelessly communicate with the remote computing device over an unencrypted wireless communication channel, and transmit, using the wireless communication module, encrypted data to the remote computing device.
Provided herein are PLIN1 RNAi agents and compositions comprising a PLIN1 RNAi agent. Also provided herein are methods of using the PLIN1 RNAi agents or compositions comprising a PLIN1 RNAi agent for reducing PLIN1 expression, and/or treating PLIN1 associated metabolic disorder in a subject.
Oral compositions including a Lp(a) inhibitor compound and histidine. Oral compositions including muvalaplin and histidine. New polymorphs of muvalaplin, such as muvalaplin hydrate Form A, muvalplin hydrate Form B, muvalaplin hemihydrate, and muvalaplin hydrate 1:6.5 mol eq. Oral compositions comprising muvalaplin hemihydrate and/or muvalaplin hydrate 1:6.5 mol eq. A method of treating a cardiovascular disease, treating an atherosclerotic cardiovascular disease, and/or lowering the level of Lp(a) in an individual by administering one of the oral compositions.
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61P 9/00 - Drugs for disorders of the cardiovascular system
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations and substances; Medicinal preparations and substances; Sanitary preparations for medical purposes; Diagnostic preparations and reagents for medical or veterinary use; Food supplements; Dietary and nutritional supplements; Dietetic food and substances adapted for medical or veterinary use; Vaccines for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations and substances; Medicinal preparations and substances; Sanitary preparations for medical purposes; Diagnostic preparations and reagents for medical or veterinary use; Food supplements; Dietary and nutritional supplements; Dietetic food and substances adapted for medical or veterinary use; Vaccines for human use.
18.
MEDICATION DELIVERY DEVICE WITH MEDICATION CARTRIDGE AND NEEDLE ASSEMBLY
Embodiments of the present disclosure relate to a medication delivery device comprising a cartridge assembly and a needle assembly. The cartridge assembly includes: a cartridge housing; and a cartridge configured to hold a fluid, wherein the cartridge is disposed in a cavity defined by an outer surface of the cartridge housing. The cartridge housing comprises a latch tooth extending from a bottom portion of the outer surface of the cartridge housing; and at least one hook portion comprising: at least one protrusion extending from at least one of two lateral portions of the outer surface; or at least one opening in the at least one of the two lateral portions of the outer surface.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations and substances; Medicinal preparations and substances; Sanitary preparations for medical purposes; Diagnostic preparations and reagents for medical or veterinary use; Food supplements; Dietary and nutritional supplements; Dietetic food and substances adapted for medical or veterinary use; Vaccines for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations and substances; Medicinal preparations and substances; Sanitary preparations for medical purposes; Diagnostic preparations and reagents for medical or veterinary use; Food supplements; Dietary and nutritional supplements; Dietetic food and substances adapted for medical or veterinary use; Vaccines for human use.
Medication delivery devices having a dosage button which automatically returns to a prime dose setting position after dosing the device by fully depressing a dose button. An injection device having an initial dose setting suited for immediately dispensing a prime dose, wherein the injection device returns to the initial prime dose setting after the dose button is activated and released.
A61M 5/36 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests with means for eliminating or preventing injection or infusion of air into body
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
22.
SYSTEMS AND METHODS FOR DETERMINING MINIMUM IGNITION ENERGIES OF DUST CLOUDS
A small-scale minimum ignition energy (MIE) testing system for estimating the MIE of a dust cloud includes a small-scale testing chamber, a supply conduit in fluid communication with a supply of test gas and defining an enclosable supply chamber having a target volume, a dispersion nozzle fluidically connected between the supply conduit and the small-scale testing chamber for receiving a sample dust, a control valve positioned along the supply conduit between the enclosable supply chamber and the dispersion nozzle, the control valve having a closed state that restricts fluid communication between the supply chamber and the small-scale testing chamber and an open state providing fluid communication between the supply chamber and the small-scale testing chamber, and a pair of electrodes coupled to the small-scale testing chamber.
G01N 25/54 - Investigating or analysing materials by the use of thermal means by investigating flash-pointInvestigating or analysing materials by the use of thermal means by investigating explosibility by determining explosibility
G01N 1/38 - Diluting, dispersing or mixing samples
F23Q 3/00 - Ignition using electrically-produced sparks
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations and substances; Medicinal preparations and substances; Sanitary preparations for medical purposes; Diagnostic preparations and reagents for medical or veterinary use; Food supplements; Dietary and nutritional supplements; Dietetic food and substances adapted for medical or veterinary use; Vaccines for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations and substances; Medicinal preparations and substances; Sanitary preparations for medical purposes; Diagnostic preparations and reagents for medical or veterinary use; Food supplements; Dietary and nutritional supplements; Dietetic food and substances adapted for medical or veterinary use; Vaccines for human use.
Oral compositions including a Lp(a) inhibitor compound and histidine. Oral compositions including muvalaplin and histidine. New polymorphs of muvalaplin, such as muvalaplin hydrate Form A, muvalaplin hydrate Form B, muvalaplin hemihydrate, and muvalaplin hydrate 1:6.5 mol eq. Oral compositions comprising muvalaplin hemihydrate and/or muvalaplin hydrate 1:6.5 mol eq. A method of treating a cardiovascular disease, treating an atherosclerotic cardiovascular disease, and/or lowering the level of Lp(a) in an individual by administering one of the oral compositions.
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 9/00 - Medicinal preparations characterised by special physical form
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations and substances; Medicinal preparations and substances; Sanitary preparations for medical purposes; Diagnostic preparations and reagents for medical or veterinary use; Food supplements; Dietary and nutritional supplements; Dietetic food and substances adapted for medical or veterinary use; Vaccines for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations and substances; Medicinal preparations and substances; Sanitary preparations for medical purposes; Diagnostic preparations and reagents for medical or veterinary use; Food supplements; Dietary and nutritional supplements; Dietetic food and substances adapted for medical or veterinary use; Vaccines for human use.
The present disclosure relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations and substances; Medicinal preparations and substances; Sanitary preparations for medical purposes; Diagnostic preparations and reagents for medical or veterinary use; Food supplements; Dietary and nutritional supplements; Dietetic food and substances adapted for medical or veterinary use; Vaccines for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations and substances; Medicinal preparations and substances; Sanitary preparations for medical purposes; Diagnostic preparations and reagents for medical or veterinary use; Food supplements; Dietary and nutritional supplements; Dietetic food and substances adapted for medical or veterinary use; Vaccines for human use.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations and substances; Medicinal preparations and substances; Sanitary preparations for medical purposes; Diagnostic preparations and reagents for medical or veterinary use; Food supplements; Dietary and nutritional supplements; Dietetic food and substances adapted for medical or veterinary use; Vaccines for human use.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and veterinary preparations and substances; Medicinal preparations and substances; Sanitary preparations for medical purposes; Diagnostic preparations and reagents for medical or veterinary use; Food supplements; Dietary and nutritional supplements; Dietetic food and substances adapted for medical or veterinary use; Vaccines for human use. Medical information in the field of obesity and weight management.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and veterinary preparations and substances; Medicinal preparations and substances; Sanitary preparations for medical purposes; Diagnostic preparations and reagents for medical or veterinary use; Food supplements; Dietary and nutritional supplements; Dietetic food and substances adapted for medical or veterinary use; Vaccines for human use. Medical information in the field of obesity and weight management.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and veterinary preparations and substances; Medicinal preparations and substances; Sanitary preparations for medical purposes; Diagnostic preparations and reagents for medical or veterinary use; Food supplements; Dietary and nutritional supplements; Dietetic food and substances adapted for medical or veterinary use; Vaccines for human use. Medical information in the field of obesity and weight management.
The present disclosure relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention provides compounds and methods targeting human interleukin-19, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of immune-mediated diseases including psoriasis, atopic dermatitis, psoriatic arthritis, bronchial asthma and diabetic nephropathy.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present invention provides novel intermediates and processes useful in the manufacture of tirzepatide, or a pharmaceutically acceptable salt thereof.
A system and method for testing a first device used for detecting data from a second device or object is described. A testing apparatus includes a reflective display configured to generate a plurality of images representing a feature of the second device or object. After the first device is positioned on the testing apparatus, an image is displayed via the reflective display, and light is emitted from the first device toward the reflective display. A light sensor of the first device receives light reflected by the reflective display and affected by the image. Test values based on the light reflected by the reflective display and affected by the image are determined and compared with expected values.
The present invention provides a compound of Formula I:
The present invention provides a compound of Formula I:
wherein R is H or
The present invention provides a compound of Formula I:
wherein R is H or
R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3,
The present invention provides a compound of Formula I:
wherein R is H or
R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3,
R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl;
R3 is NH2, or CH2NH2; and
X is O, OCH2, OCH2CH2, OCH(CH3), CH2O, SCH2, CH2S, CH2, NHCH2, CH2NH, N(CH3)CH2, CH2CH2, C≡C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis and rheumatoid arthritis.
C07J 71/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton is condensed with a heterocyclic ring
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
C07B 59/00 - Introduction of isotopes of elements into organic compounds
Provided are crystalline forms of peptide fragments, method of preparation thereof, and use thereof for preparing peptides. The present crystalline compounds may be employed as intermediates with improved purity and physical properties for peptide syntheses.
Relaxin (RLN) analogs are disclosed including modifications that increase half-life when compared to native, human RLN, that maintain selectivity to the RXFP1 receptor and that provide in vitro and in vivo stability for improved druggability properties and less immunogenicity. Pharmaceutical compositions also are disclosed that include one or more of the RLN analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the RLN analogs also are disclosed, especially for treating cardiovascular, pulmonary and/or renal conditions, diseases or disorders.
A61K 38/30 - Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Incretin analogs are provided that have activity at each of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and obesity.
The present invention provides novel intermediates and processes useful in the manufacture of tirzepatide, or a pharmaceutically acceptable salt thereof.
Aspects of the disclosure relate to methods and systems for solid phase oligonucleotide synthesis (SPOS). In some embodiments, the methods described by the disclosure comprise systems and methods related to washing after deblocking during solid phase oligonucleotide synthesis. In some embodiments, used deblocking solution is combined with a used washing solution and distilled to provide a distillate wash solution that can be used in a later washing step. In some embodiments, wash solutions are heated or pyridine is added for use during countercurrent washing procedures to increase efficiency. In some embodiments, the methods are combined.
Aspects of the disclosure relate to methods and systems for solid phase oligonucleotide synthesis (SPOS). In some embodiments, the methods described by the disclosure comprise a step of oxidation reaction solution recycling. In some embodiments, recycling the oxidation reaction solution requires a significantly reduced amount of oxidation solution during the entire SPOS process relative to SPOS processes where the oxidation step of each cycle is carried out using fresh oxidation solution. In some embodiments, oligonucleotides produced using systems and methods of the disclosure have higher purity than oligonucleotides produced using conventional SPOS techniques.
Aspects of the disclosure relate to methods and systems for solid phase oligonucleotide synthesis (SPOS). In some embodiments, the methods described by the disclosure comprise a step of capping reaction solution recycling. In some embodiments, recycling the capping reaction solution requires a significantly reduced amount of capping solution during the entire SPOS process relative to SPOS processes where the capping step of each cycle is carried out using fresh oxidation solution. In some embodiments, oligonucleotides produced using systems and methods of the disclosure have higher purity than oligonucleotides produced using conventional SPOS techniques
Aspects disclosed herein relate to methods and systems for performing Solid Phase Oligonucleotide Synthesis (SPOS). In some embodiments, a system configured for use in SPOS may include an obstruction (e.g., a bar) that is configured to disrupt cohesion of a resin cake during SPOS to promote fluidization and mixing of the resin with a reagent. In some embodiments, a system configured for use in SPOS may include one or more spray devices (e.g., spray nozzles and/or spray balls), where the spray devices may be configured to provide solvents and/or reagents to the resin. The spray devices may also be configured to provide wash solvent to wash the walls of the reactor vessel.
Aspects of the disclosure relate to methods and systems for solid phase oligonucleotide synthesis (SPOS). In some embodiments, the methods described by the disclosure comprise a step of performing a deblocking step (e.g., a detritylation reaction) during each cycle of the SPOS reaction. In some embodiments, performing the deblocking steps with neat or high concentration DCA addback to the reuse acid solution during deblocking, reuse DCA-rich portion of post-detritylation ACN wash as part of the deblocking process, using the distillation bottoms is used as part of the deblocking process, or deblocking in FBR with thiol scavengers requires a significantly reduced amount of deblocking reagent, such as acid solution, during the entire SPOS process relative to SPOS processes where the deblocking step is carried out at room temperature.
C07H 1/00 - Processes for the preparation of sugar derivatives
B01J 2/00 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
The present disclosure provides compounds of the formula:
The present disclosure provides compounds of the formula:
The present disclosure provides compounds of the formula:
and their pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising these compounds and their use in the treatment of type II diabetes mellitus and obesity.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
52.
SYSTEMS AND METHODS FOR DETECTING STATE OF A MEDICATION DELIVERY DEVICE
A sensing system for determining a state of a compression spring is provided. The system may include capacitive plates positioned on opposite sides of the compression spring, a temperature sensor, and at least one processing circuit configured to measure a capacitance between the capacitive plates, measure a temperature based on a signal output by the temperature sensor, and determine whether the compression spring is in a compressed state or an expanded state based on the measured capacitance and the measured temperature. In some embodiments, the sensing system may be used to detect a state of a compression spring disposed on or within a medication-delivery device, so as to determine a state of the medication-delivery device. For example, the sensing system may be used to determine whether the medication-delivery device has been activated, or whether the device has completed delivery of the medication.
Disclosed herein are dosing regimens for the administration of a compound of Formula (I) or Formula (II): or a combination thereof, or in combination with a second therapeutic agent, for use in treating cancer, preferably FGFR3-associated cancer, in a patient in need of such treatment.
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present disclosure is directed to methods of purifying a dulaglutide composition. For example, the methods comprise loading the dulaglutide composition in-line with a buffer B solution onto a hydrophobic interaction chromatography (HIC) column in a downflow direction, washing the HIC column with a buffer mixture of a buffer A solution and the buffer B solution in the downflow direction, and eluting dulaglutide from the HIC column. A linear gradient of a percentage of the buffer A and buffer B solutions is used for eluting dulaglutide, which is then followed by an isocratic hold based on a UV absorbance reading of an eluate. The methods further comprise maintaining the isocratic hold until a front side cut is made, and then dropping the buffer B solution for dulaglutide to elute from the HIC column.
The present invention relates to antibodies that bind to human CDI37 and display agonist activity, and are useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorder, alopecia, Alzheimer’s disease, asthma, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, cancer, cardiovascular disease, central nervous system diseases and disorders, Crohn’s disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, obstructive sleep apnea, osteoarthritis, pain, Parkinson’s disease, psoriasis, psoriatic arthritis, retinal disease, rheumatoid arthritis, ulcerative colitis, vascular diseases and vision loss; pharmaceutical preparations for weight management. Medical information services in the field of diabetes; Providing health and wellness information to patients and caregivers in the field of diabetes.
Provided herein are conjugates for selective delivery of a therapeutic molecule, such as an oligonucleotide, to adipose tissue. In particular, the conjugate includes a NPR-C binding peptide, a therapeutic agent (e.g., an oligonucleotide), and optionally a linker conjugating the peptide to the therapeutic agent. The conjugates can also include one or more fatty acids. Also provided herein are methods and uses of treating diseases and conditions associated with adipose tissue (e.g., obesity or obesity-related comorbidity) by the conjugates described herein.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Provided herein are SOD1 RNAi agents and compositions comprising a SOD1 RNAi agent. Also provided herein are methods of using the SOD1 RNAi agents or compositions comprising a SOD1 RNAi agent in reducing SOD1 expression and/or treating SOD1-mediated neurological disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Antibodies that bind UNC5C and fragments thereof are described. Compositions comprising these antibodies, as well as methods, including therapeutic methods and therapeutic uses of the antibodies are also described.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
66.
ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CHRONIC PAIN
vvSCN9Avvv1.7 protein in cells of the peripheral nervous system, preferably large nociceptor cells (type Aα/Aβ), to provide a treatment of chronic pain.
A compound comprising a progranulin domain, a TfR1 binding domain, and optionally an albumin binding domain when administered to a patient, such as a human, can: (1) modulate tau in the patient, (2) lead to the reduction of tau in a patient previously having elevated tau, (3) lead to the prevention of tau tangles in a patient without elevated tau or in a patient having elevated tau, and/or (4) prevent the accumulation of tau in a patient without elevated tau and/or prevent a patient's tau levels from becoming elevated. Treatment and prevention of a neurodegenerative disease through the administration of the compound.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
12344 are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients with cancer.
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
123a3b1233 are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients with cancer.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
A battery depletion prevention module configured to be coupled to a medication delivery device is provided. In some embodiments, the battery depletion prevention module comprises: an actuator; and a processing circuit comprising: a microcontroller; a battery configured to supply power to the microcontroller; and a power control module comprising a timer and at least one switch. In some embodiments, in response to the actuator switching to an engaged state: the power-on switch is configured to close, thereby causing an increase in power supplied by the battery to the microcontroller, and the timer is configured to be activated. In some embodiments, in response to the actuator remaining in the engaged state for a threshold amount of time since activation of the timer, the power control module is configured to switch to a power-off state, thereby causing a decrease in power supplied by the battery to the microcontroller.
The invention pertains to a method for reducing amyloid plaques in the brain of a human suffering from a disease characterized by Aβ plaques in the brain, e.g., Alzheimer's disease. The invention also relates to a method for preventing or reducing amyloid plaques in the brain of a primary prevention subject. Certain aspects of the invention involve methods, doses, or dosing regimens that decrease the risk, frequency, severity, or occurrence of ARIA in subjects.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
Syringe systems and methods are provided for delivering injectable drugs. A syringe includes a syringe barrel including a distal end, a proximal end, a bore extending therebetween, a plunger received in the bore, and a plunger rod coupled to move the plunger. A plunger rod retainer is removably coupled to the plunger rod and configured to retain the plunger at a fixed position inside the bore, and a volume is disposed in the bore between the distal end of the syringe barrel and the plunger. When the syringe is at a first configuration, the volume includes a gas having a reduced pressure, and when the syringe is at a second configuration, the volume includes an injectable drug.
Provided herein are molecules that bind to the N-terminal and C-terminal regions of tirzepatide and uses thereof, including methods for detecting tirzepatide in a sample.
The present disclosure provides compounds of the formula:
The present disclosure provides compounds of the formula:
The present disclosure provides compounds of the formula:
and their pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising these compounds and their use in the treatment of type II diabetes mellitus and obesity.
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 498/02 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
Provided herein are compounds of the formula:
3 are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients with cancer.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/4741 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
96.
METHODS OF USING AND COMPOSITIONS INCLUDING AN INCRETIN ANALOG
Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.
Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.
Provided herein are antibody conjugates comprising a bis-MSPT linker, pharmaceutical compositions comprising such conjugates, and methods of making or using such conjugates.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; medical preparations; veterinary preparations; Sanitary preparations for medical purposes; Dietetic food and substances adapted for medical purposes; Dietetic food and substances adapted for veterinary purposes; food for babies; Dietary and nutritional supplements for human beings; Dietary and nutritional supplements for animals; Adhesive plasters; Materials for dressings; Materials for tooth fillings; dental wax; Disinfectants; Preparations for destroying vermin; Fungicides; Herbicides.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; medical preparations; veterinary preparations; Sanitary preparations for medical purposes; Dietetic food and substances adapted for medical purposes; Dietetic food and substances adapted for veterinary purposes; food for babies; Dietary and nutritional supplements for human beings; Dietary and nutritional supplements for animals; Adhesive plasters; Materials for dressings; Materials for tooth fillings; dental wax; Disinfectants; Preparations for destroying vermin; Fungicides; Herbicides.
